Renub Research

www.renub.com
Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast Global Analysis

Published: December, 2013

Copyright 2013 Renub Research All Rights Reserved

Alzheimers disease drug market is on the curvature stage. Since 2003, there is not any single magic bullet launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimers disease drug market. From the year 2009 Alzheimers disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimers drugs from the year 2017 onwards, Alzheimers disease drug market is expected to revive in the coming years. However due to absence of exact potential drugs there will always remain a huge Unmet Alzheimers Drug Market. For the year 2018 Alzheimers Disease Drug M arket will be just 10% of Unmet Alzheimers Disease Drug Market. Renub Research study titled Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast Global Analysis provides a comprehensive assessment of the fastevolving, high-growth Global Alzheimers Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimers Disease Drug Market. Present & Pipeline Alzheimers Drugs Studied in this Report 1. Namenda 2. Ebixa 3. Axura 4. Aricept 5. Nootropil 6. Exelon 7. Memary 8. Solanezumab 9. LuAe58054 This report contains 10 chapters.

Renub Research

Page 2 of 12

(Chapter 1): Executive Summary (Chapter 2): This Chapter is divided into 2 parts A. Alzheimers Disease Drug Market & Forecast data available from 2003 to 2018 B. Unmet Alzheimers Disease Drug Market & Forecast (Market Potential) data available from 2010 to 2018. (Unmet market is the potential market which could have been achieved if right drug have been introduced in the market) (Chapter 3): This chapter talks about drugs which has failed while in Clinical trials (Chapter 4): This chapter provides Market Share of Alzheimers Disease Drug from 2003 to 2018. All the 9 Alzheimers drug mentioned above have been covered in th is chapter. (Chapter 5): This chapter talks about Alzheimers Drugs performance. All important drugs mentioned above past, present & future market data available from 2003 to 2018. (Chapter 6): Pipeline drugs (Solanezumab, LuAE58054, Gantenerumab, Crenezumab, TRx0237 (LMTX), MK-8931, ABT-126, AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points: A. Clinical Development Stage B. Pipeline Drug Sales Performance C. Recent Clinical Development D. Different Companies Deal E. Investment (Chapter 7): This chapter speaks of Alzheimers Drugs Company deals in four areas A. Strategic Alliances in Alzheimers Disease Drug Market B. Licensing Agreement in Alzheimers Disease Drug Market C. Collaboration Deal in Alzheimers Disease Drug Market D. Merger & Acquisition in Alzheimers Disease Drug Market
Renub Research Page 3 of 12

(Chapter 8): This chapter studies Funding in Alzheimers Disease Drugs Research . We have covered 5 institutes which provides fund for the research. A. National Institute of Health B. Alzheimer's Association C. Cure Alzheimers Fund D. Alzheimers Drug Discovery Foundation E. BrightFocus Foundation [formerly American Health Assistance Foundation (AHAF)] (Chapter 9): This chapter studies Growth Factors Driving the Alzheimers Disease Drug Market. (Chapter 10): This chapter studies Challenges/Hindrances faced by Alzheimers Disease Drug Market.

Data Sources This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts. Primary sources include industry surveys and telephone interviews with industry experts. Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Renub Research

Page 4 of 12

Table of Contents
1. Executive Summary

2.

Worldwide Alzheimers Disease Drug Market Analysis 2.1 2.2 Alzheimers Disease Drug Market & Forecast Unmet Alzheimers Disease Drug Market & Forecast (Market Potential)

3.

Failed Alzheimers Drugs 3.1 Dismal Results but Still Trying Again

4.

Worldwide Alzheimers Disease Drug Market Share & Forecast

5.

Worldwide Alzheimers Drug Brands Market Performance 5.1 5.2 5.3 Exelon (Rivastigmine) Past, Present & Future Market Aricept (Donepezil) Past, Present & Future Market Memantine (Namenda, Ebixa, Axura, Memary) Past, Present & Future Market Namenda (Memantine) Past, Present & Future Market Ebixa (Memantine) Past, Present & Future Market Axura (Memantine) Past, Present & Future Market Memary (Memantine) Past, Present & Future Market

5.3.1 5.3.2 5.3.3 5.3.4 5.4

Nootropil (Piracetam) Past, Present & Future Market

6.

Pipeline Drugs Analysis in Alzheimers Disease Market 6.1 Solanezumab (LY2062430) Eli Lilly Clinical Development Stage Phase II Phase III Solanezumab Drug Sales (2017 2020) Recent Clinical Development

6.1.1 6.1.1.1 6.1.1.2 6.1.2 6.1.3

Renub Research

Page 5 of 12

6.2

LuAE58054 Lundbeck Clinical Development Stage Phase II LuAE58054 Drug Sales (2017 2018) Deal on LuAE58054

6.2.1 6.2.1.1 6.2.2 6.2.3

6.3

Gantenerumab Roche Clinical Development Stage Phase I Phase II & III Phase III Investment in Gantenerumab Drug 6.3.1.1 6.3.1.2 6.3.1.3

6.3.1

6.3.2

6.4

Crenezumab Genentech Clinical Development Stage Phase II Investment in Crenezumab Drug

6.4.1 6.4.1.1 6.4.2

6.5

TRx0237 (LMTX) TauRx Therapeutics Ltd. Clinical Development Stage Phase II Phase III Investment in TRx0237 (LMTX) Drug 6.5.1.1 6.5.1.2

6.5.1

6.5.2

6.6

MK-8931 Merck Clinical Development Stage Phase II/III

6.6.1 6.6.1.1

6.7

ABT-126 AbbVie Clinical Development Stage Phase I Phase II 6.7.1.1 6.7.1.2

6.7.1

6.8

AZD-1446 Targacept/AstraZeneca Clinical Development Stage Page 6 of 12

6.8.1

Renub Research

6.8.1.1 6.8.2

Phase I Recent Development

7.

M&A, Licensing Agreement, Strategic Alliances & Collaboration Deals in Alzheimers Disease

Drug Market 7.1 7.2 7.3 7.4 Strategic Alliances in Alzheimers Disease Drug Market Licensing Agreement in Alzheimers Disease Drug Market Collaboration Deal in Alzheimers Disease Drug Market Merger & Acquisition in Alzheimers Disease Drug Market

8.

Funding in Alzheimers Disease Drugs Research 8.1 8.2 8.3 8.4 8.5 National Institute of Health Alzheimer's Association Cure Alzheimers Fund Alzheimers Drug Discovery Foundation BrightFocus Foundation [formerly American Health Assistance Foundation (AHAF)]

9.

Key Drivers of Growth in Global Alzheimers Disease Drug Market 9.1 Aging Population Global Ageing Indicators Population Aged 60 or Over: World and Development Regions, 1950 2050 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950

9.1.1 9.1.2 9.1.3 2050 9.2 9.3

Unmet Medical Needs The Launches of New Drugs Solanezumab, LuAE58054, Gantenerumab & TRx0237 Will Boost

the Alzheimers Market Through 2018 9.4 Future Drugs for Disease Modification in Alzheimers Disease

10. 10.1

Key Challenges in the Global Alzheimers Disease Drug Market Lack of Validated Targets & Lack of Animal Models

Renub Research

Page 7 of 12

10.2 10.3 10.4 10.5 10.6

Barriers in the Design and Implementation of Clinical Trials Barriers in Academia & Regulatory Issues Alzheimers Drug Failure: Insinuation for Future R&D in Neuroscience Costly Alzheimers Drug Development Dissuade Drug Companies Research Setbacks and Stepping Stones

List of Figures

Figure 2-1: Worldwide Alzheimers Disease Drug Market (Million US$), 2003 2012 Figure 2-2: Worldwide Forecast for Alzheimers Disease Drug Market (Million US$), 2013 2018 Figure 2-3: Worldwide Unmet Alzheimers Disease Drug Market (Million US$), 2010 2012 Figure 2-4: Worldwide Forecast for Unmet Alzheimers Disease Drug Market (Million US$), 2013 2018 Figure 5-1: Worldwide Exelon Alzheimers Drug Sales (Million US$), 2005 2012 Figure 5-2: Worldwide Forecast for Exelon Alzheimers Drug Sales (Million US$), 2013 2018 Figure 5-3: Worldwide Aricept Alzheimers Drug Sales (Million US$), 2004 2012 Figure 5-4: Worldwide Forecast for Aricept Alzheimers Drug Sales (Million US$), 2013 2018 Figure 5-5: Worldwide Namenda Alzheimers Drug Sales (Million US$), 2003 2012 Figure 5-6: Worldwide Forecast for Namenda Alzheimers Drug Sales (Million US$), 2013 2018 Figure 5-7: Worldwide Ebixa Alzheimers Drug Sales (Million US$), 2003 2012 Figure 5-8: Worldwide Forecast for Ebixa Alzheimers Drug Sales (Million US$), 2013 2018 Figure 5-9: Worldwide Axura Alzheimers Drug Sales (Million US$), 2003 2012 Figure 5-10: Worldwide Forecast for Axura Alzheimers Drug Sales (Million US$), 2013 2018 Figure 5-11: Worldwide Memary Alzheimers Drug Sales (Million US$), 2011 2012 Figure 5-12: Worldwide Forecast for Memary Alzheimers Drug Sales (Million US$), 2013 2018 Figure 5-13: Worldwide Nootropil Alzheimers Drug Sales (Million US$), 2004 2012 Figure 5-14: Worldwide Forecast for Nootropil Alzheimers Drug Sales (Million US$), 2013 2018 Figure 6-1: Worldwide Forecast for Pipeline Solanezumab Drug Sales (Million US$), 2017 2020 Figure 6-2: Worldwide Forecast for Pipeline LuAE58054 Drug Sales (Million US$), 2017 2018

Figure 8-1: National Institute of Health Funding in Alzheimers Disease Research (Million US$), 2003 2013 Figure 8-2: Alzheimers Association Funding in Alzheimers Disease Research (Million US$), 2007 2013 Renub Research Page 8 of 12

Figure 8-3: Cure Alzheimers Fund Funding in Alzheimers Disease Research (Million US$), 2007 2012 Figure 8-4: Alzheimers Drug Discovery Foundation Funding in Alzheimers Disease Research (Million US$), 2007 2012 Figure 9-1: Worldwide Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050 Figure 9-2: Worldwide Old-Age Dependency Ratio: Major Areas, 2009 & 2050 Figure 9-3: Worldwide - Distribution of population aged 60 years or over by broad age group, 1950 2050 Figure 9-4: Worldwide Pipeline Alzheimers Drugs Performance (Million US$), 2009, 2015, 2017 Figure 10-1: Unsuccessful Alzheimers Drug Development (Number), 1998 2011

List of Tables:

Table 4-1: Worldwide Alzheimers Disease Drug Market Share (Percent), 2003 2012 Table 4-2: Worldwide Forecast for Alzheimers Disease Drug Market Share (Percent), 2013 2018 Table 6-1: Alzheimers Disease Investment in Crenezumab Drug (Million US$), 2012 Table 7-1: Strategic Alliances in Alzheimers disease Drug Market, 2003 2013 Table 7-2: Licensing Agreement in Alzheimers disease Drug Market, 2007 2013 Table 7-3: Collaboration Deal in Alzheimers Disease Drug Market, 2005 2013 Table 7-4: Merger & Acquisition (Million US$) in Alzheimers disease Drug Market, 2008 2013 Table 8-1: BrightFocus Foundation Funding in Alzheimers disease Research (US$), 2010 2013 Table 9-1: Global Ageing Indicators (Percent), 2011/2012 2050 Table 9-2: Global Population (Number), 2011/2012 2050 Table 9-3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 & 2100(Medium Variant)

Renub Research

Page 9 of 12

Order Form
Scan and e-mail this page to info@renub.com. Else you can also fax this form to +91-120-4249780 Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to info@renub.com

Format
Report Title: Cancer Test Market & Forecast, Companies Cancer Test Platform, Pipeline Analysis and Clinical Trials Global

Single User (Email from Publisher) US$ 1,475

Hard Copy (Mail Delivery) US$ 1,675

CD Rom (Mail Delivery) US$ 1,575

Global Site License (Multiple User License) US$ 2,100

For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.): http://www.renub.com/report/alzheimers-pipeline-drugs-review-alzheimers-disease-drugmarket-forecast---global-analysis-127 2) Order by Wire Transfer: http://www.renub.com/report/wiretransfer.aspx?id=127&pid=1502 To pay by Wire Transfer, please, fill in your contact details in the form below:

Renub Research

Page 10 of 12

Bank Details
Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi 110001 India

Contact Information
First Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message: Last Name:

Renub Research

Page 11 of 12

3) Order by Check Please post the check accompanied by this form, to: Company Address: Renub Research 1st Floor, C-86, Sector-10 Noida - 201301 Uttar Pradesh India Phone: +91-120-421-9822, 424-9780

For free Sample copy report or to view any of our sample work please contact us at info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)

Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090 LinkedIn: http://www.linkedin.com/company/renub-research Twitter: http://twitter.com/RenubResearch

Renub Research

Page 12 of 12